Zhejiang Qianjiang Biochemical Co Ltd
Zhejiang Qianjiang Biochemical Co Ltd is engaged in the production and sale of biochemical products, primarily serving the industrial and commercial services sector.
Business. Zhejiang Qianjiang Biochemical Co Ltd (600796.SS) is a company operating within the Construction & Engineering industry, classified under the broader Industrials sector. The firm is headquartered in China and is primarily listed on the Shanghai Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Zhejiang Qianjiang Biochemical Co Ltd (600796.SS) is a company operating within the Construction & Engineering industry, classified under the broader Industrials sector. The firm is headquartered in China and is primarily listed on the Shanghai Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Zhejiang Qianjiang Biochemical Co Ltd has a market capitalization of 4.67 billion CNY, with a market price of 5.39 CNY per share. The company has 866,585,766 basic and diluted shares outstanding, indicating no immediate dilution risk from share issuance. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
Profitability and return metrics are not available for direct comparison to industry medians, as the valuation snapshot does not include ROIC, EBITDA margins, or other key performance indicators. The company's financial structure and returns are therefore opaque in the context of its industry peers.
The company's revenue concentration and geographic exposure are not disclosed in the available data, making it difficult to assess the risk associated with overreliance on specific markets or customer segments.
Growth trajectory is also unclear, as the outlook for the current and next fiscal years does not include numeric deltas or directional guidance. Without historical revenue data, it is not possible to determine whether the company is experiencing growth or contraction.
Risk factors include the inability to assess liquidity risk, which could impact the company's ability to meet short-term obligations. The absence of balance-sheet inputs and lack of going-concern language in source documents suggest a potential information gap that investors should consider.
Recent events, including filings and transcripts, are not available in the provided data, limiting the ability to assess the company's recent strategic or operational developments.
- The company has no immediate dilution risk, as basic and diluted shares outstanding are equal.
- Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language in source documents.
- Profitability and return metrics are not available for comparison to industry medians.
- Revenue concentration and geographic exposure are not disclosed, limiting visibility into market risk.
- Growth trajectory is unclear due to the absence of numeric deltas or directional guidance in the outlook.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Zhejiang Qianjiang Biochemical Co Ltd Market data — financials · 2026-05-27
Ownership & reference
Leadership
- Haijun ShaoExecutive Chairman of the Board